Reimbursement of IVD tests has a complex environment in France, and it consists of the Nomenclature of Medical Biology Services (NABM), RIHN Nomenclature for innovative tests outside the Nomenclature of biology and anatomocytopathology, and the Supplementary list of medical biology and anatomocytopathology services. RIHN catalog includes innovative tests with the objective of testing their value prior to the integration into NABM. Tests are funded outside social security insurance via research and innovation budget (MERRI, part of MIGAC budget) distributed by the Ministry of Health. The Supplementary list includes tests, which were initially considered innovative, but for which a decision either about discontinuing reimbursement or about introduction in the NABM catalog should be made. The Supplementary list is also funded via the MERRI budget.
On March 22, the 2021 repository of innovative laboratory tests (RIHN) and the Supplementary list of medical biology and anatomocytopathology services were published. However, no new codes were included in the catalogs, and no codes were removed or transferred. In the Supplementary list, only minor modifications in the comments for the codes have been introduced.
The 2021 RIHN catalog and Supplementary list can be downloaded here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).